Source: http://www.freshpatents.com/-dt20121025ptan20120270837.php
Timestamp: 2017-02-22 10:41:49
Document Index: 420128691

Matched Legal Cases: ['§119', 'application No. 60', 'application No. 60', '§119', 'application No. 60', 'application No. 60']

Compositions That Treat Or Inhibit Pathological Conditions Associated With Inflammatory Response (Metaproteomics) Toggle navigation
Compositions that treat or inhibit pathological conditions associated with inflammatory response / Metaproteomics, Llc
Title: Compositions that treat or inhibit pathological conditions associated with inflammatory response.Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof. ...
Browse recent Metaproteomics, Llc patentsUSPTO Applicaton #: #20120270837 Inventors: Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, Deann J. Liska, Terrence Howell
The Patent Description & Claims data below is from USPTO Patent Application 20120270837, Compositions that treat or inhibit pathological conditions associated with inflammatory response.
This application is a continuation of U.S. application Ser. No. 11/729,696, filed Mar. 29, 2007, now U.S. Pat. No. 8,168,234, which is a divisional of U.S. application Ser. No. 10/689,856, filed on Oct. 20, 2003, now U.S. Pat. No. 7,270,835, which is a continuation-in-part of U.S. application Ser. No. 10/464,410, filed Jun. 18, 2003; now U.S. Pat. No. 8,142,819, which is a continuation-in-part of U.S. application Ser. No. 10/400,293, filed Mar. 26, 2003, now abandoned, and a continuation-in-part of U.S. application Ser. No. 10/401,283, filed Mar. 26, 2003, now abandoned, both of which claim the benefit under 35 U.S.C. §119(e) to provisional application No. 60/450,237, filed on Feb. 25, 2003, and provisional application No. 60/420,383, filed on Oct. 21, 2002; and is a continuation-in-part of U.S. patent application Ser. No. 10/464,834, filed Jun. 18, 2003, now abandoned, which is a continuation-in-part of U.S. application Ser. No. 10/400,293, filed Mar. 26, 2003, and a continuation-in-part of U.S. application Ser. No. 10/401,283, filed Mar. 26, 2003, both of which claim the benefit under 35 U.S.C. §119(e) to provisional application No. 60/450,237, filed on Feb. 25, 2003, and provisional application No. 60/420,383, filed on Oct. 21, 2002. This application is also a continuation-in-part of U.S. application Ser. No. 09/885,721, filed Jun. 20, 2001, now U.S. Pat. No. 7,205,151. The contents of each of these earlier applications are hereby incorporated by reference as if recited herein in their entirety.
The present invention relates generally to compositions that can be used to treat or inhibit pathological conditions associated with tissue-specific activation of inflammation and/or NFκB, to methods of modulating inflammation, including in cells, and to methods of modulating NFκB in cells. More specifically, the invention relates to a composition comprising hops extracts or derivatives thereof or a fraction isolated or derived from hops, which can optionally be combined with a second component, such as rosemary, an extract derived from rosemary, a compound derived from rosemary, a triterpene species, a diterpene lactone species, and tryptanthrin. The invention further relates to methods of using the compositions to inhibit expression of cyclooxygenase-2 (COX-2), inhibit synthesis of prostaglandins selectively in target cells, inhibit inflammatory responses selectively in target cells, and/or inhibit NFκB activation selectively in target cells.
U.S. patent application 2002/0086070A1 of Kuhrts entitled, “ANTI-INFLAMMATORY AND CONNECTIVE TISSUE REPAIR FORMULATIONS” describes a hops component that has an IC50—WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33. Example 1 of the application describes a composition containing an extract obtained through supercritical carbon dioxide extraction of whole hops (CO2-extract) comprising 42% humulone.
← Previous Next → Advertise on FreshPatents.com - Rates & InfoYou can also Monitor Keywords and Search for tracking patents relating to this Compositions that treat or inhibit pathological conditions associated with inflammatory response patent application.
Browse recent Metaproteomics, Llc patents
How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Compositions that treat or inhibit pathological conditions associated with inflammatory response or other areas of interest.###
Previous Patent Application:Therapeutic approaches for treating alzheimer's diseaseNext Patent Application:Compositions and methods for cancer treatmentIndustry Class:Drug, bio-affecting and body treating compositionsThank you for viewing the Compositions that treat or inhibit pathological conditions associated with inflammatory response patent info.- - - Results in 1.05218 seconds
Browse patents: Next Prev Patent InfoApplication # US 20120270837 A1Publish Date 10/25/2012 Document # File Date 12/31/1969 USPTO Class Other USPTO Classes International Class / Drawings 0 Inflammatory Response Follow us on Twitter@FreshPatents
Metaproteomics, LlcBrowse recent Metaproteomics, Llc patentsDrug, Bio-affecting And Body Treating Compositions Designated Organic Active Ingredient Containing (doai) O-glycoside Glucosamine Or Derivative Browse patents: Next Prev Aircraft
20121025|20120270837|compositions that treat or inhibit pathological conditions associated with inflammatory response|A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments |Metaproteomics-Llc